Previous 10 | Next 10 |
SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (...
Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus pla...
2023-08-12 10:15:17 ET Journey Medical Corporation (DERM) Q2 2023 Earnings Conference Call August 8 2023 4:00 PM ET Company Participants Matt Blazei - CoreIR Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Interim Chief Financi...
2023-08-08 17:30:40 ET Journey Medical press release ( NASDAQ: DERM ): Q2 GAAP EPS of -$0.46 misses by $0.12 . Revenue of $17.2M (-6.0% Y/Y) beats by $2.39M . For further details see: Journey Medical GAAP EPS of -$0.46 misses by $0.12, revenue of $17.2M b...
The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 Announced positive topline results from two Phase 3 clinical trials evaluating DFD-29 (minocycline hydrochloride modified release capsu...
Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET Company and Neal Bhatia, MD, Director of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA and Investigator in over 75 clinical trials includin...
2023-08-01 05:25:31 ET Summary B. Riley Financial's recent equity raise suggests one of two scenarios, an acknowledgment of untenable dividend policy, or an effort to recalibrate its financial leverage, restoring balance to its sheets. Despite marketing its diversification strateg...
SCOTTSDALE, Ariz., July 19, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutic...
2023-07-11 13:19:00 ET Gainers: Eloxx Pharmaceuticals ( ELOX ) +112% . CytoMed Therapeutics Limited ( GDTC ) +102% . Biodexa Pharmaceuticals ( BDRX ) +92% . SOS Limited ( SOS ) +39% . Freeline Therapeutics Holdings ( FRLN ) +33% ...
2023-07-11 10:06:43 ET Gainers: CytoMed Therapeutics ( GDTC ) +128% . Eloxx Pharmaceuticals ( ELOX ) +29% . UpHealth ( UPH ) +13% . Virios Therapeutics ( VIRI ) +13% . Acumen Pharmaceuticals ( ABOS ) +9% . Losers: Jou...
News, Short Squeeze, Breakout and More Instantly...
Journey Medical Corporation Company Name:
DERM Stock Symbol:
NASDAQ Market:
Journey Medical Corporation Website:
2024-06-17 22:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (...
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the...